International Clinical Trial: An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07812181) titled 'An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder' on Sept. 4.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jonathan Santoro

Condition: Down Syndrome Regression Disorder (DSRD) Down Syndrome (Trisomy 21) Neuroinflammatory / Neuropsychiatric Disorder

Intervention: Drug: Ublituximab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 1, 2026

Target Sample Size: 20

Countries of ...